Enric Limon

Dr. Enric Limon

Programa VINCat, Institut Català d'Oncologia, Barcelona, Catalonia, Spain
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
NFN. Freixas
N. Freixas
FBF. Bella
F. Bella
Enric LimonEnric Limon
Enric Limon
MPMiquel Pujol
Miquel Pujol
BAB. Almirante
B. Almirante
FGF. Gudiol
F. Gudiol

1 July 2019 in Journal of Hospital Infection
Verified
Journal Article
Closed access
MAM. Abbas
M. Abbas
MKM.E.A. de Kraker
M.E.A. de Kraker
EAE. Aghayev
E. Aghayev
PAP. Astagneau
P. Astagneau
MAM. Aupee
M. Aupee
SHS. Harbarth
S. Harbarth

12 May 2022 in Eurosurveillance
Verified
Journal Article
Open access
LBLaia Badia-Cebada
Laia Badia-Cebada
JPJudit Peñafiel
Judit Peñafiel
PSPatrick Saliba
Patrick Saliba
MAMarta Andrés
Marta Andrés
JCJordi Càmara
Jordi Càmara
OPOn Behalf Of The Vincat Programme (Infection Control Catalan Programme)
On Behalf Of The Vincat Programme (Infection Control Catalan Programme)
Background: Catheter-related bloodstream infections (CRBSI) are frequent healthcare-associated infections and an important cause of death. Aim: To analyse changes in CRBSI epidemiology observed by the Infection Control Catalan Programme (VINCat). Methods: A cohort study including all hospital-acquired CRBSI episodes diagnosed at 55 hospitals (2007–2019) in Catalonia, Spain, was prospectively conducted. CRBSI incidence rates were adjusted per 1,000 patient days. To assess the CRBSI rate trend per year, negative binomial models were used, with the number of events as the dependent variable, and the year as the main independent variable. From each model, the annual rate of CRBSI diagnosed per 1,000 patient days and the incidence rate ratio (IRR) with its 95% confidence intervals (CI) were reported. Results: During the study, 9,290 CRBSI episodes were diagnosed (mean annual incidence rate: 0.20 episodes/1,000 patient days). Patients’ median age was 64.1 years; 36.6% (3,403/9,290) were female. In total, 73.7% (n = 6,845) of CRBSI occurred in non-intensive care unit (ICU) wards, 62.7% (n = 5,822) were related to central venous catheter (CVC), 24.1% (n = 2,236) to peripheral venous catheters (PVC) and 13.3% (n = 1,232) to peripherally-inserted central venous catheters (PICVC). Incidence rate fell over the study period (IRR: 0.94; 95%CI: 0.93–0.96), especially in the ICU (IRR: 0.88; 95%CI: 0.87–0.89). As a whole, while episodes of CVC CRBSI fell significantly (IRR: 0.88; 95%CI: 0.87–0.91), peripherally-inserted catheter CRBSI (PVC and PICVC) rose, especially in medical wards (IRR PICVC: 1.08; 95%CI: 1.05–1.11; IRR PVC: 1.03; 95% 1.00-1.05). Conclusions: Over the study, CRBSIs associated with CVC and diagnosed in ICUs decreased while episodes in conventional wards involving peripherally-inserted catheters increased. Hospitals should implement preventive measures in conventional wards.

4 August 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
Santiago GrauSantiago Grau
Santiago Grau
SHSergi Hernández
Sergi Hernández
Daniel Echeverria-EsnalDaniel Echeverria-Esnal
Daniel Echeverria-Esnal
AAAlexander Almendral
Alexander Almendral
RFRicard Ferrer
Ricard Ferrer
O(On Behalf Of The Catalan Infection Control Antimicrobial Stewardship Program (Vincat-Proa)
On Behalf Of The Catalan Infection Control Antimicrobial Stewardship Program (Vincat-Proa)
Background: Antimicrobials have been widely used during the COVID-19 pandemic. This study aimed to analyze the impact of the COVID-19 pandemic on the antimicrobial consumption of 66 hospitals in Catalonia. Methods: Adult antibacterial and antimycotic consumption was calculated as defined daily doses (DDD)/100 bed-days and DDD/100 discharges. Firstly, overall and ICU consumption in 2019 and 2020 were compared. Secondly, observed ICU 2020 consumptions were compared with non-COVID-19 2020 estimated consumptions (based on the trend from 2008–2019). Results: Overall, antibacterial consumption increased by 2.31% and 4.15% DDD/100 bed-days and DDD/100 discharges, respectively. Azithromycin (105.4% and 109.08% DDD/100 bed-days and DDD/100 discharges, respectively) and ceftriaxone (25.72% and 27.97% DDD/100 bed-days and DDD/100 discharges, respectively) mainly accounted for this finding. Likewise, antifungal consumption increased by 10.25% DDD/100 bed-days and 12.22% DDD/100 discharges, mainly due to echinocandins or amphotericin B. ICU antibacterial and antimycotic consumption decreased by 1.28% and 4.35% DDD/100 bed-days, respectively. On the contrary, antibacterial and antifungal use, expressed in DDD/100 discharges, increased by 23.42% and 19.58%. Azithromycin (275.09%), ceftriaxone (55.11%), cefepime (106.35%), vancomycin (29.81%), linezolid (31.28%), amphotericin B (87.98%), and voriconazole (96.17%) use changed the most. Observed consumption of amphotericin B, azithromycin, caspofungin, ceftriaxone, vancomycin, and voriconazole were higher than estimated values. Conclusions: The consumption indicators for most antimicrobials deviated from the expected trend pattern. A worrisome increase in antibacterial and antifungal consumption was observed in ICUs in Catalonia.

21 April 2017 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
OGon behalf of VINCat colon surgery group
on behalf of VINCat colon surgery group
AGAina Gomila
Aina Gomila
JCJordi Carratala
Jordi Carratala
DFDaniel Camprubí Ferrer
Daniel Camprubí Ferrer
ESEvelyn Shaw
Evelyn Shaw
MPMiquel Pujol
Miquel Pujol
Organ-space surgical site infections (SSI) are the most serious and costly infections after colorectal surgery. Most previous studies of risk factors for SSI have analysed colon and rectal procedures together. The aim of the study was to determine whether colon and rectal procedures have different risk factors and outcomes for organ-space SSI. A multicentre observational prospective cohort study of adults undergoing elective colon and rectal procedures at 10 Spanish hospitals from 2011 to 2014. Patients were followed up until 30 days post-surgery. Surgical site infection was defined according to the Centers for Disease Control and Prevention criteria. Oral antibiotic prophylaxis (OAP) was considered as the administration of oral antibiotics the day before surgery combined with systemic intravenous antibiotic prophylaxis. Of 3,701 patients, 2,518 (68%) underwent colon surgery and 1,183 (32%) rectal surgery. In colon surgery, the overall SSI rate was 16.4% and the organ-space SSI rate was 7.9%, while in rectal surgery the rates were 21.6% and 11.5% respectively (p < 0.001). Independent risk factors for organ-space SSI in colon surgery were male sex (Odds ratio -OR-: 1.57, 95% CI: 1.14–2.15) and ostomy creation (OR: 2.65, 95% CI: 1.8–3.92) while laparoscopy (OR: 0.5, 95% CI: 0.38–0.69) and OAP combined with intravenous antibiotic prophylaxis (OR: 0.7, 95% CI: 0.51–0.97) were protective factors. In rectal surgery, independent risk factors for organ-space SSI were male sex (OR: 2.11, 95% CI: 1.34–3.31) and longer surgery (OR: 1.49, 95% CI: 1.03–2.15), whereas OAP with intravenous antibiotic prophylaxis (OR: 0.49, 95% CI: 0.32–0.73) was a protective factor. Among patients with organ-space SSI, we found a significant difference in the overall 30-day mortality, being higher in colon surgery than in rectal surgery (11.5% vs 5.1%, p = 0.04). Organ-space SSI in colon and rectal surgery has some differences in terms of incidence, risk factors and outcomes. These differences could be considered for surveillance purposes and for the implementation of preventive strategies. Administration of OAP would be an important measure to reduce the OS-SSI rate in both colon and rectal surgeries.

1 April 2008 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
AMA. Manzur
A. Manzur
ADA.M. Dominguez
A.M. Dominguez
MPMiquel Pujol
Miquel Pujol
MGM.P.M. González
M.P.M. González
Enric LimonEnric Limon
Enric Limon
JAJ. Ariza
J. Ariza